Gene · 4437
Papers3,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reclassification of variants of tumor suppressor genes based on Sanger RNA sequencing without NMD inhibition. | Front Genet | 2023 | 37900184 | PubTator, text mining | PubMed |
| Multiple Primary Melanoma: A Five-Year Prospective Single-Center Follow-Up Study of Two MC1R R/R Genotype Carriers. | Life (Basel) | 2023 | 37895483 | PubTator, text mining | PubMed |
| A New Frameshift Mutation of PTEN Gene Associated with Cowden Syndrome-Case Report and Brief Review of the Literature. | Genes (Basel) | 2023 | 37895258 | PubTator, text mining | PubMed |
| AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells. | Int J Mol Sci | 2023 | 37895013 | PubTator, text mining | PubMed |
| Chemical Insights into Oxidative and Nitrative Modifications of DNA. | Int J Mol Sci | 2023 | 37894920 | PubTator, text mining | PubMed |
| Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics. | Cancers (Basel) | 2023 | 37894443 | PubTator, text mining | PubMed |
| Histone and DNA Methylation as Epigenetic Regulators of DNA Damage Repair in Gastric Cancer and Emerging Therapeutic Opportunities. | Cancers (Basel) | 2023 | 37894343 | PubTator, text mining | PubMed |
| Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate‑resistant human colorectal cancer cells. | Int J Oncol | 2023 | 37888748 | PubTator, text mining | PubMed |
| Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. | J Pers Med | 2023 | 37888109 | PubTator, text mining | PubMed |
| Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma. | Res Sq | 2023 | 37886584 | PubTator, text mining | PubMed |
| Structural Variation Detection and Association Analysis of Whole-Genome-Sequence Data from 16,905 Alzheimer's Diseases Sequencing Project Subjects. | Res Sq | 2023 | 37886469 | PubTator, text mining | PubMed |
| The haplotype-resolved T2T reference genome highlights structural variation underlying agronomic traits of melon. | Hortic Res | 2023 | 37885818 | PubTator, text mining | PubMed |
| Testing for deficient mismatch repair and microsatellite instability : A focused update. | Pathologie (Heidelb) | 2023 | 37874379 | PubTator, text mining | PubMed |
| PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer. | Ther Adv Med Oncol | 2023 | 37868079 | PubTator, text mining | PubMed |
| Mutational topography reflects clinical neuroblastoma heterogeneity. | Cell Genom | 2023 | 37868040 | PubTator, text mining | PubMed |
| Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone. | BMC Cancer | 2023 | 37864137 | PubTator, text mining | PubMed |
| Genetic modifiers of repeat expansion disorders. | Emerg Top Life Sci | 2023 | 37861103 | PubTator, text mining | PubMed |
| The Largest Chinese Cohort Study Indicates Homologous Recombination Pathway Gene Mutations as Another Major Genetic Risk Factor for Colorectal Cancer with Heterogeneous Clinical Phenotypes. | Research (Wash D C) | 2023 | 37854294 | PubTator, text mining | PubMed |
| Next-generation sequencing in dermatology. | Front Med (Lausanne) | 2023 | 37841001 | PubTator, text mining | PubMed |
| Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study. | Cancers (Basel) | 2023 | 37835512 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4437/papers?page=10